UPPSALA, Sweden, Nov. 3, 2003 (PRIMEZONE) -- The Shareholders of Pyrosequencing AB (publ), Reg. No. 556539-3138, are hereby summoned to an extraordinary general meeting of shareholders to be held on Wednesday 3 December 2003, at 5 pm at Mannheimer Swartling Advokatbyra AB, Norrmalmstorg 4 in Stockholm, Sweden.
Notice etc.,
Shareholders that wish to participate in the general meeting of shareholders shall a) be listed in the register of shareholders held by VPC AB as of Friday, 21 November 2003 and b) notify their intention to participate in the meeting not later than Friday, 28 November 2003, before 4 p.m. Notice of participation in the general meeting of shareholders may be made in writing to the Company at the address Vallongatan 1, 752 28 Uppsala, Sweden by fax+46 18 59 19 22, by telephone +46 18-56 59 00 or by e-mail: deltagare@pyrosequencing.com. When making the notice, the following data should be included: name, social security number/corporate registration number, address, telephone number, shareholdings and number of accompanying assistants (maximum two).
In order to be entitled to participate at the general meeting of shareholders, shareholders whose shares are nominee registered must temporarily re-register the shares at VPC AB in their own names. Shareholders that wish to make such re-registration must notify their nominees of such intention well in advance of Friday 21 November, 2003.
Proposed agenda
1. Opening of the meeting
2. Election of a Chairman of the meeting
3. Preparation and approval of the voting register
4. Adoption of the agenda for the meeting
5. Election of two persons to attest the minutes of the meeting
6. Determination of whether the meeting has been duly convened
7. Proposed resolution; to amend # 1 in the Articles of
Association
8. Closing of the meeting been duly convened
Proposed resolution (item 7) The board of directors proposes the general meeting of shareholders to change Company name to Biotage AB and that the general meeting of shareholders therefore resolves that #1 of the Articles of Association shall have the following amended wording.
Current wording # 1
The Company name shall be Pyrosequencing AB. The Company is public (publ).
Proposed wording (amendments in italic) # 1 The Company name shall be Biotage AB. The Company is public (publ).
About the New Company
Pyrosequencing accelerates the drug discovery and development process and increases the knowledge of the importance of the genetic make-up by providing complete solutions for medicinal chemistry research and applied genetic analysis. Through its merger with Personal Chemistry the company has further strengthened its customer base of commercial and academic partners, which include the world's top 20 pharmaceutical companies and prestigious academic institutes such as the US National Institutes of Health, the US Centers for Disease Control and Prevention and Sweden's Karolinska Institute. Headquartered in Uppsala, Sweden, Pyrosequencing has facilities in Boston, USA, Cambridge, UK and Constance, Germany. After the acquisition of Biotage the company will have approx. 275 employees. Pro-forma the new group had sales of 427 MSEK in 2002. The company is listed on the Stockholm stock exchange. Website: www.pyrosequencing.com
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as ``believe," ``expect," ``intend," and ``should," among others. These forward-looking statements are based on Pyrosequencing's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/11/03/20031103BIT20020/wkr0005.pdf